FOXO3 and cancer: Because FOXO3a is typically inactivated in human cancers by phosphorylation rather than mutation, modulation of this pathway has attracted attention as a potential anti-cancer therapeutic strategy (Farhan et al., 2017; Liu et al., 2018; Yang and Hung, 2009; Zanella and Carnero, 2009).